SEC Comment Letter for BIOCRYST PHARMACEUTICALS (BCRX) — Dec 14, 2021
BIOCRYST PHARMACEUTICALS INC
Date: Dec. 14, 2021 · CIK: 0000882796 · Accession: 0000000000-21-014940
AI Filing Summary & Sentiment
File numbers found in text: 000-23186
Letter
United States securities and exchange commission logo December 14, 2021 Alane Barnes Chief Legal Officer BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 Re:BioCryst Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 000-23186 Dear Ms. Barnes: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2020 Notes to Consolidated Financial Statements Note 3. Royalty Monetizations, page 64 1.We see that you used level 3 inputs to determine the fair value of the ORLADEYO royalty financing obligation. Please tell us where you provided all of the relevant disclosures required by ASC 820-10-50, including quantitative information about the significant unobservable inputs used in the fair value measurement.
FirstName LastNameAlane Barnes Comapany NameBioCryst Pharmaceuticals, Inc. December 14, 2021 Page 2 FirstName LastName Alane Barnes BioCryst Pharmaceuticals, Inc. December 14, 2021 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Kristin Lochhead at (202) 551-3664 or Brian Cascio, Accounting Branch Chief, at (202) 551-3676 if you have questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 14, 2021
Alane Barnes
Chief Legal Officer
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
Re:BioCryst Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed March 1, 2021
File No. 000-23186
Dear Ms. Barnes:
We have reviewed your filing and have the following comment. In our comment, we
may ask you to provide us with information so we may better understand your disclosure.
Please respond to this comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this comment, we may have additional comments.
Form 10-K for the Fiscal Year Ended December 31, 2020
Notes to Consolidated Financial Statements
Note 3. Royalty Monetizations, page 64
1.We see that you used level 3 inputs to determine the fair value of the
ORLADEYO royalty financing obligation. Please tell us where you provided all of the
relevant disclosures required by ASC 820-10-50, including quantitative information about
the significant unobservable inputs used in the fair value measurement.
FirstName LastNameAlane Barnes
Comapany NameBioCryst Pharmaceuticals, Inc.
December 14, 2021 Page 2
FirstName LastName
Alane Barnes
BioCryst Pharmaceuticals, Inc.
December 14, 2021
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Kristin Lochhead at (202) 551-3664 or Brian Cascio, Accounting
Branch Chief, at (202) 551-3676 if you have questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences